- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Personalized Medicine: It May be High Cost, but It's Higher Value
Personalized medicine will be expensive in these early days of pioneering and planning. But individual genomic testing is not going to be exorbitant forever — and the ROI is gonna be big, both in patient outcomes and dollars saved.
Personalized medicine will be expensive in these early days of pioneering and planning. But individual genomic testing is not going to be exorbitant forever — and the ROI is gonna be big, both in patient outcomes and dollars saved, said a panel of speakers at MedCity’s CONVERGE conference in Philadelphia.
“Because pharmacogenomics is rooted in the pathobiology of disease, the implications of that are going to be huge moving forward,” said Hakon Hakonarson, director of the Center for Applied Genomics, The Children’s Hospital of Philadelphia. “But in the short term it’s going to be more expensive.”
To bridge the gap between today and a future where personalized medicine is the norm, companies are reaching for the low-hanging fruit: Cancer.
Read the full story here: http://bit.ly/UdU3Rd
Source: Med City News
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
